Total debt rose to $49.5B from $31.1B in 2024Q3 and debt-to-equity peaked at 2.43 before easing to 1.23, suggesting leverage is improving as the equity base rebuilds, though the thin $4.9B cash buffer warrants attention.
Eli Lilly and Company (LLY) balance sheet — 30-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 65.26B | 55.63B | 32.74B | 25.73B | 18.03B | 18.45B | 17.46B | 13.71B | 20.55B | 19.2B | 15.1B | 12.57B | 11.93B | 13.1B | 13.04B | 14.25B | 14.84B | 12.49B | 12.45B | 12.32B | 9.69B | 10.8B | 12.84B | 8.76B | 7.8B | 6.94B | 7.94B | 7.06B | 5.41B | 5.32B | 3.89B |
| Cash & Short-Term Investments | 4.88B | 7.27B | 3.42B | 2.93B | 2.21B | 3.91B | 3.68B | 2.44B | 7.41B | 8.03B | 6.04B | 4.45B | 4.83B | 5.4B | 5.68B | 6.9B | 6.73B | 4.5B | 5.93B | 4.83B | 3.89B | 5.04B | 7.46B | 3.71B | 3.65B | 3.73B | 4.62B | 3.84B | 1.5B | 1.95B | 813.7M |
| Cash Only | 4.88B | 7.16B | 3.27B | 2.82B | 2.07B | 3.82B | 3.66B | 2.34B | 7.32B | 6.54B | 4.58B | 3.67B | 3.87B | 3.83B | 4.02B | 5.92B | 5.99B | 4.46B | 5.5B | 3.22B | 3.11B | 3.01B | 5.37B | 2.76B | 1.95B | 2.7B | 4.11B | 3.7B | 1.5B | 1.95B | 813.7M |
| Short-Term Investments | 0 | 105M | 154.8M | 109.1M | 144.8M | 90.1M | 24.2M | 101M | 88.2M | 1.5B | 1.46B | 785.4M | 955.4M | 1.57B | 1.67B | 974.6M | 733.8M | 34.7M | 429.4M | 1.61B | 781.7M | 2.03B | 2.1B | 957M | 1.71B | 1.03B | 503.3M | 135.6M | 0 | 0 | 0 |
| Accounts Receivable | 25.23B | 20.16B | 13.28B | 11.34B | 8.56B | 8.13B | 6.93B | 5.54B | 5.78B | 5.26B | 4.77B | 4.07B | 3.8B | 4.02B | 3.89B | 4.24B | 4.16B | 3.83B | 3.28B | 3.7B | 2.69B | 2.76B | 2.55B | 2.34B | 2.07B | 1.7B | 1.97B | 1.84B | 2.24B | 1.88B | 1.74B |
| Days Sales Outstanding | 95.02 | 112.87 | 107.58 | 121.25 | 109.45 | 104.75 | 103.06 | 90.62 | 98.1 | 96.16 | 81.98 | 74.46 | 70.73 | 63.53 | 62.79 | 63.69 | 65.77 | 64.05 | 58.72 | 72.57 | 62.68 | 68.83 | 67.24 | 67.95 | 68.34 | 53.61 | 66.07 | 67.24 | 88.66 | 86.05 | 90.6 |
| Inventory | 18.19B | 13.74B | 7.59B | 5.77B | 4.31B | 3.89B | 3.98B | 3.19B | 3.1B | 4.46B | 3.56B | 3.45B | 2.74B | 2.93B | 2.64B | 2.3B | 2.52B | 2.85B | 2.49B | 2.52B | 2.27B | 1.88B | 2.29B | 1.96B | 1.5B | 1.06B | 883.1M | 899.6M | 999.9M | 900.7M | 881.4M |
| Days Inventory Outstanding | 407.96 | 453.91 | 329.06 | 297.52 | 237.27 | 193.96 | 264.95 | 246.68 | 241.54 | 365.87 | 227.68 | 249.69 | 202.76 | 217.81 | 201.19 | 165.64 | 210.47 | 244.93 | 207.92 | 216.8 | 233.66 | 197.3 | 259.45 | 267.84 | 250.78 | 179.14 | 198.98 | 198.01 | 239.37 | 228.91 | 242.14 |
| Other Current Assets | 91M | 147M | 111.4M | 149.5M | 7.3M | 0 | 0 | 0 | 2.23B | 0 | 0 | 0 | 0 | 0 | 0 | 654.9M | 608.9M | 271M | 382.1M | 642.8M | 519.2M | 756.4M | 255.3M | 490.4M | 331.7M | 223.3M | 475.6M | 477.1M | 667.5M | 589.3M | 459.1M |
| Total Non-Current Assets | 82.81B | 56.85B | 45.98B | 38.28B | 31.46B | 30.35B | 29.17B | 25.58B | 23.36B | 25.78B | 23.7B | 23B | 24.38B | 22.14B | 21.36B | 19.41B | 16.16B | 14.97B | 16.76B | 14.56B | 12.26B | 13.79B | 12.03B | 12.92B | 11.24B | 9.5B | 6.75B | 5.77B | 7.19B | 7.26B | 10.42B |
| Property, Plant & Equipment | 32.19B | 24.68B | 17.1B | 12.91B | 10.14B | 8.99B | 8.68B | 8.4B | 8B | 8.83B | 8.25B | 8.05B | 7.96B | 7.98B | 7.76B | 7.76B | 7.94B | 8.2B | 8.63B | 8.58B | 8.15B | 7.91B | 7.55B | 6.54B | 5.29B | 4.53B | 4.18B | 3.98B | 4.1B | 4.1B | 4.31B |
| Fixed Asset Turnover | 3.07x | 2.64x | 2.63x | 2.64x | 2.81x | 3.15x | 2.83x | 2.66x | 2.69x | 2.26x | 2.57x | 2.48x | 2.46x | 2.90x | 2.91x | 3.13x | 2.91x | 2.66x | 2.36x | 2.17x | 1.92x | 1.85x | 1.84x | 1.92x | 2.09x | 2.55x | 2.60x | 2.51x | 2.25x | 1.95x | 1.62x |
| Goodwill | 9.87B | 5.9B | 5.77B | 4.94B | 4.07B | 3.89B | 3.77B | 3.68B | 1.37B | 4.37B | 3.97B | 4.04B | 1.76B | 1.52B | 1.5B | 1.43B | 1.42B | 1.18B | 1.17B | 745.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 18.08B | 6.52B | 6.17B | 6.91B | 7.21B | 7.69B | 7.45B | 6.62B | 1.07B | 4.03B | 4.36B | 5.03B | 2.88B | 2.81B | 3.25B | 3.69B | 3.39B | 2.52B | 2.89B | 1.71B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 118.6M | 1.52B | 1.55B | 4.03B |
| Long-Term Investments | 13.79B | 2.8B | 3.22B | 3.05B | 2.9B | 3.21B | 2.97B | 1.96B | 2.02B | 5.68B | 5.21B | 3.65B | 4.57B | 7.62B | 6.31B | 4.03B | 1.78B | 1.16B | 1.54B | 577.1M | 1B | 1.3B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 7.7B | 6.99B | 5.72B | 4.99B | 4.34B | 4.08B | 3.48B | 2.34B | 8.3B | 2.87B | 1.91B | 2.22B | 5.74B | 1.42B | 1.49B | 2.49B | 1.62B | 1.92B | 2.15B | 2.37B | 3.11B | 4.58B | 4.48B | 6.38B | 5.94B | 4.96B | 2.57B | 1.67B | 1.57B | 1.6B | 2.08B |
| Total Assets | 148.07B | 112.48B | 78.71B | 64.01B | 49.49B | 48.81B | 46.63B | 39.29B | 43.91B | 44.98B | 38.81B | 35.57B | 36.31B | 35.25B | 34.4B | 33.66B | 31B | 27.46B | 29.21B | 26.79B | 21.96B | 24.58B | 24.87B | 21.68B | 19.04B | 16.43B | 14.69B | 12.83B | 12.6B | 12.58B | 14.31B |
| Asset Turnover | 0.67x | 0.58x | 0.57x | 0.53x | 0.58x | 0.58x | 0.53x | 0.57x | 0.49x | 0.44x | 0.55x | 0.56x | 0.54x | 0.66x | 0.66x | 0.72x | 0.74x | 0.80x | 0.70x | 0.70x | 0.71x | 0.60x | 0.56x | 0.58x | 0.58x | 0.70x | 0.74x | 0.78x | 0.73x | 0.64x | 0.49x |
| Asset Growth % | 143.12% | 42.89% | 22.98% | 29.33% | 1.4% | 4.66% | 18.7% | -10.53% | -2.38% | 15.91% | 9.1% | -2.03% | 3% | 2.47% | 2.2% | 8.58% | 12.89% | -6% | 9.05% | 22.01% | -10.68% | -1.15% | 14.71% | 13.84% | 15.87% | 11.87% | 14.55% | 1.82% | 0.14% | -12.09% | -0.73% |
| Total Current Liabilities | 47B | 35.23B | 28.38B | 27.29B | 17.14B | 15.05B | 12.48B | 11.78B | 11.89B | 14.54B | 10.99B | 8.23B | 11.21B | 8.92B | 8.39B | 8.93B | 7.1B | 6.57B | 13.11B | 5.27B | 5.09B | 5.72B | 7.59B | 5.55B | 5.06B | 5.2B | 4.96B | 3.94B | 4.61B | 4.19B | 4.22B |
| Accounts Payable | 5.79B | 5.38B | 3.23B | 2.6B | 1.93B | 1.67B | 1.61B | 1.41B | 1.21B | 1.41B | 1.35B | 1.34B | 1.13B | 1.12B | 1.19B | 1.13B | 1.07B | 968.1M | 885.8M | 924.4M | 789.4M | 781.3M | 648.6M | 875.9M | 676.9M | 624.1M | 661.9M | 445.5M | 1.19B | 985.5M | 829.3M |
| Days Payables Outstanding | 143.89 | 177.65 | 139.99 | 133.94 | 106.29 | 83.38 | 106.95 | 108.64 | 94.11 | 115.77 | 86.25 | 96.97 | 83.48 | 83.24 | 90.43 | 81.04 | 89.63 | 83.2 | 73.87 | 79.41 | 81.24 | 82.08 | 73.43 | 119.51 | 113.52 | 105.45 | 149.14 | 98.06 | 283.92 | 250.46 | 227.83 |
| Short-Term Debt | 2.52B | 1.64B | 5.12B | 6.9B | 1.5B | 1.54B | 8.7M | 1.5B | 1.1B | 3.71B | 1.94B | 6.1M | 2.69B | 1.01B | 11.9M | 1.52B | 156M | 27.4M | 5.85B | 413.7M | 219.4M | 734.7M | 2.02B | 196.5M | 545.4M | 286.3M | 184.3M | 241.5M | 181.4M | 227.6M | 1.21B |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 12.22B | 28.21B | 7.15B | 4.93B | 3.91B | 10.68B | 9.3B | 3.1B | 3.69B | 7.82B | 6.61B | 3.43B | 3.76B | 4.72B | 4.99B | 5.15B | 4.56B | 4.33B | 5.32B | 3.06B | 3.42B | 3.65B | 4.45B | 4.48B | 3.84B | 4.29B | 4.11B | 3.25B | 3.24B | 2.98B | 2.18B |
| Current Ratio | 1.39x | 1.58x | 1.15x | 0.94x | 1.05x | 1.23x | 1.40x | 1.16x | 1.73x | 1.32x | 1.37x | 1.53x | 1.06x | 1.47x | 1.55x | 1.60x | 2.09x | 1.90x | 0.95x | 2.34x | 1.91x | 1.89x | 1.69x | 1.58x | 1.54x | 1.33x | 1.60x | 1.79x | 1.17x | 1.27x | 0.92x |
| Quick Ratio | 1.00x | 1.19x | 0.89x | 0.73x | 0.80x | 0.97x | 1.08x | 0.89x | 1.47x | 1.01x | 1.05x | 1.11x | 0.82x | 1.14x | 1.24x | 1.34x | 1.74x | 1.47x | 0.76x | 1.86x | 1.46x | 1.56x | 1.39x | 1.22x | 1.25x | 1.13x | 1.42x | 1.56x | 0.96x | 1.05x | 0.71x |
| Cash Conversion Cycle | 359.09 | 389.13 | 296.65 | 284.84 | 240.44 | 215.33 | 261.06 | 228.65 | 245.53 | 346.26 | 223.41 | 227.18 | 190.01 | 198.09 | 173.55 | 148.29 | 186.61 | 225.78 | 192.77 | 209.96 | 215.09 | 184.05 | 253.26 | 216.28 | 205.61 | 127.29 | 115.91 | 167.19 | 44.11 | 64.5 | 104.91 |
| Total Non-Current Liabilities | 60.8B | 50.71B | 36.07B | 25.85B | 21.58B | 24.6B | 28.33B | 24.81B | 21.11B | 18.78B | 13.74B | 12.75B | 11.18B | 8.69B | 11.24B | 11.19B | 11.49B | 11.37B | 9.37B | 7.93B | 5.89B | 8.07B | 6.35B | 6.36B | 5.7B | 4.13B | 3.68B | 3.88B | 3.56B | 3.58B | 3.98B |
| Long-Term Debt | 46.99B | 40.87B | 28.53B | 18.32B | 14.74B | 15.35B | 16.59B | 13.82B | 9.2B | 9.93B | 8.37B | 7.97B | 5.35B | 4.2B | 5.52B | 5.46B | 6.77B | 6.63B | 4.62B | 4.59B | 3.49B | 5.76B | 4.49B | 4.69B | 4.36B | 3.13B | 2.63B | 2.81B | 2.19B | 2.33B | 2.52B |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 486.7M | 0 | 0 | 0 | 0 | 18.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 5.46B | 0 | 0 | 0 | 87.3M | 1.73B | 2.1B | 2.19B | 1.31B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 84.8M | 74.7M | 287.5M | 62.2M | 695.1M | 620.4M | 0 | 0 | 0 | 91.6M | 137M | 247.9M | 215.5M | 376M |
| Other Non-Current Liabilities | 13.82B | 9.85B | 7.54B | 7.53B | 6.75B | 7.52B | 9.64B | 8.32B | 10.6B | 8.85B | 5.37B | 4.78B | 5.85B | 4.49B | 5.72B | 5.73B | 4.72B | 4.65B | 4.68B | 3.05B | 2.33B | 1.61B | 1.24B | 1.67B | 1.35B | 995M | 957.9M | 927.9M | 1.13B | 1.04B | 1.09B |
| Total Liabilities | 107.8B | 85.94B | 64.44B | 53.14B | 38.71B | 39.65B | 40.81B | 36.59B | 33B | 33.31B | 24.73B | 20.98B | 20.92B | 17.61B | 19.63B | 20.12B | 18.59B | 17.94B | 22.48B | 13.37B | 10.97B | 13.79B | 13.95B | 11.91B | 10.77B | 9.33B | 8.64B | 7.81B | 8.17B | 7.77B | 8.21B |
| Total Debt | 49.5B | 42.5B | 33.64B | 25.23B | 16.24B | 16.88B | 16.6B | 15.8B | 10.3B | 13.65B | 10.31B | 7.98B | 8.06B | 5.21B | 5.53B | 6.99B | 6.93B | 6.66B | 10.46B | 5.01B | 3.71B | 6.5B | 6.51B | 4.88B | 4.9B | 3.42B | 2.82B | 3.05B | 2.37B | 2.55B | 3.73B |
| Net Debt | 44.62B | 35.34B | 30.38B | 22.41B | 14.17B | 13.07B | 12.94B | 13.47B | 2.98B | 7.11B | 5.72B | 4.31B | 4.18B | 1.38B | 1.51B | 1.06B | 933.3M | 2.2B | 4.97B | 1.79B | 604.5M | 3.49B | 1.15B | 2.13B | 2.96B | 716.1M | -1.3B | -647M | 871.2M | 606.2M | 2.92B |
| Debt / Equity | 1.23x | 1.60x | 2.36x | 2.32x | 1.51x | 1.84x | 2.85x | 5.86x | 0.94x | 1.17x | 0.73x | 0.55x | 0.52x | 0.30x | 0.37x | 0.52x | 0.56x | 0.70x | 1.55x | 0.37x | 0.34x | 0.60x | 0.60x | 0.50x | 0.59x | 0.48x | 0.47x | 0.61x | 0.53x | 0.53x | 0.61x |
| Debt / EBITDA | 1.18x | 1.34x | 1.79x | 2.05x | 1.60x | 1.78x | 1.94x | 2.19x | 1.35x | 2.35x | 1.92x | 1.59x | 1.71x | 0.75x | 0.85x | 0.91x | 0.86x | 0.87x | 1.57x | 0.86x | 0.75x | 1.49x | 1.53x | 1.21x | 1.28x | 0.82x | 0.71x | 0.80x | 0.71x | 0.87x | 1.44x |
| Net Debt / EBITDA | 1.06x | 1.12x | 1.62x | 1.82x | 1.39x | 1.38x | 1.52x | 1.86x | 0.39x | 1.22x | 1.07x | 0.86x | 0.89x | 0.20x | 0.23x | 0.14x | 0.12x | 0.29x | 0.75x | 0.31x | 0.12x | 0.80x | 0.27x | 0.53x | 0.77x | 0.17x | -0.32x | -0.17x | 0.26x | 0.21x | 1.13x |
| Interest Coverage | 36.14x | 37.34x | 21.83x | 14.49x | 21.53x | 19.12x | 21.11x | 14.15x | 16.18x | 11.24x | 19.22x | 18.31x | 21.16x | 37.79x | 31.42x | 29.76x | 36.18x | 21.50x | -4.73x | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 40.27B | 26.54B | 14.27B | 10.86B | 10.78B | 9.15B | 5.83B | 2.7B | 10.91B | 11.67B | 14.08B | 14.59B | 15.39B | 17.64B | 14.77B | 13.54B | 12.41B | 9.53B | 6.74B | 13.5B | 10.98B | 10.79B | 10.92B | 9.76B | 8.27B | 7.1B | 6.05B | 5.01B | 4.43B | 4.81B | 6.1B |
| Equity Growth % | 336.28% | 85.93% | 31.37% | 0.82% | 17.7% | 57.16% | 115.82% | -75.26% | -6.5% | -17.13% | -3.49% | -5.18% | -12.77% | 19.4% | 9.15% | 9.05% | 30.31% | 41.42% | -50.12% | 22.98% | 1.75% | -1.17% | 11.83% | 18.02% | 16.46% | 17.48% | 20.62% | 13.17% | -7.82% | -21.22% | 12.29% |
| Book Value per Share | 45.08 | 29.55 | 15.79 | 12.03 | 11.34 | 9.60 | 6.09 | 2.82 | 10.55 | 11.09 | 12.79 | 13.20 | 13.86 | 15.80 | 12.89 | 12.15 | 11.23 | 8.67 | 6.15 | 12.38 | 10.10 | 9.87 | 10.01 | 9.04 | 7.64 | 6.52 | 5.52 | 4.53 | 3.95 | 4.25 | 5.46 |
| Total Shareholders' Equity | 40.27B | 26.54B | 14.19B | 10.77B | 10.65B | 8.98B | 5.64B | 2.61B | 9.83B | 11.59B | 14.01B | 14.57B | 15.37B | 17.63B | 14.77B | 13.54B | 12.42B | 9.52B | 6.74B | 13.5B | 10.98B | 10.79B | 10.92B | 9.76B | 8.27B | 7.1B | 6.05B | 5.01B | 4.43B | 4.65B | 6.1B |
| Common Stock | 588M | 590M | 592.4M | 593.6M | 594.1M | 596.3M | 598.2M | 598.8M | 661M | 687.9M | 688.5M | 691.3M | 694.6M | 698.5M | 716.6M | 724.1M | 721.3M | 0 | 0 | 709.5M | 0 | 706.9M | 708M | 702.3M | 702.1M | 702.7M | 704.4M | 682M | 0 | 0 | 0 |
| Retained Earnings | 37.97B | 24.47B | 13.54B | 10.31B | 10.04B | 8.96B | 7.83B | 4.92B | 11.4B | 13.89B | 16.05B | 16.01B | 16.48B | 16.99B | 16.09B | 14.9B | 12.73B | 9.83B | 7.65B | 11.81B | 10.93B | 10.03B | 9.72B | 9.47B | 8.5B | 7.41B | 6.22B | 4.99B | 4.23B | 4.48B | 7.21B |
| Treasury Stock | 0 | 0 | -49.5M | -44.2M | -50.5M | -52.7M | -55.7M | -60.8M | -69.4M | -75.8M | -80.5M | -90M | -91.4M | -93.6M | -192.4M | -95.3M | -96.4M | -98.5M | -99.2M | -100.5M | -101.4M | -104.1M | -103.8M | -104.2M | -109.5M | -107.4M | -109.5M | -108.3M | 0 | 0 | 0 |
| Accumulated OCI | -2.63B | -2.88B | -4.32B | -4.33B | -3.84B | -4.34B | -9.51B | -6.52B | -8.74B | -8.73B | -8.29B | -4.58B | -3.99B | -2B | -3.8B | -3.86B | -2.67B | -2.47B | -5.51B | -2.72B | -4.12B | -3.16B | -2.53B | -2.91B | -3.43B | -3.51B | -3.38B | -546.3M | 0 | 0 | -2.79B |
| Minority Interest | 0 | 0 | 79.5M | 91.8M | 125.6M | 175.6M | 183.6M | 92.2M | 1.08B | 75.7M | 72.8M | 19M | 14.9M | 9.3M | 8.7M | -6.1M | -7.5M | 1.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 160M | 0 |
Quick answers to the most common questions about buying LLY stock.
As of 2025, Eli Lilly and Company (LLY) had total assets of $112.48B including $55.63B in current assets.
Eli Lilly and Company (LLY) carries total debt of $42.50B, offset by $7.27B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Eli Lilly and Company (LLY) has total shareholders' equity (book value) of $26.54B ($29.55 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Eli Lilly and Company (LLY) reported a current ratio of 1.58x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Leverage rising with debt scaling
Metrics are mathematically derived from official filings.
Equity Base Rebuilding Alongside Rising Debt
According to reported quarterly figures, LLY's equity rose from $14.2B in 2024Q2 to $40.3B in 2026Q3, while total assets nearly doubled to $148.1B over the same ten-quarter window.
The balance sheet appears to be strengthening on an absolute basis, driven largely by retained earnings growing from $13.5B to $38.0B. This suggests profits are being retained and reinvested rather than fully distributed, which may indicate management's preference for funding growth internally. Investors should monitor whether this earnings-driven equity build keeps pace with the expanding asset base.
Leverage Elevated but Falling Recently
Based on LLY's reported figures, the debt-to-equity ratio peaked at 2.43 in 2025Q1 before easing to 1.23 in 2026Q3, while total debt climbed to $49.5B from $31.1B in 2024Q3.
The recent improvement in D/E reflects equity growing faster than debt, rather than debt reduction, since total debt remains near multi-year highs. This pattern suggests leverage was taken on to support manufacturing and acquisition activity, with earnings now absorbing it. Refinancing exposure and the cost of servicing a $49.5B debt stack warrant further investigation as rate conditions evolve.
Thin Cash Buffer Against Large Obligations
As reported in financial statements, LLY's cash position fell to $4.9B in 2026Q3 from $8.9B in the prior quarter, while the current ratio held at 1.39, indicating current assets still cover short-term liabilities.
A current ratio above 1.0 provides adequate near-term coverage, but the sharp drop in cash relative to a $148.1B asset base suggests cash has been deployed into operations, capital projects, or acquisitions. The low absolute cash balance relative to total debt may reduce flexibility if earnings soften. This appears to rely on continued operating cash generation for liquidity.
Asset Growth Tilted Toward Manufacturing and Intangibles
According to recent SEC filings, LLY's net PP&E grew from $14.8B to $32.2B over ten quarters, while goodwill expanded from $5.8B to $9.9B, signaling a more capital-intensive and acquisition-linked asset mix.
The PP&E build-out is consistent with the parenteral and fill-finish capacity investment noted in prior analysis, suggesting the business is becoming more asset-heavy. Goodwill growth points to acquired intangibles, which carry impairment risk if acquired products underperform. Taken together, the asset mix may increase sensitivity to both utilization rates and acquisition outcomes.
Equity Growth Masks Concentration Dependence
Based on reported figures, LLY's return on equity of roughly 101% reflects a small and rapidly growing equity base, which may overstate capital efficiency if earnings remain concentrated in the metabolic franchise.
Because equity has expanded substantially through retained earnings, the headline ROE may appear exceptional partly due to the denominator's rapid change and the compressed equity base in earlier periods. The high return is interpretive of a single therapeutic category rather than a diversified earnings base. Investors should monitor whether ROE normalizes as the equity base continues to grow.